

TABLE OF CONTENTS

Arrhythmias and Thrombosis I	1
Arrhythmias and Thrombosis I Panel	3

Atrial Fibrillation/Atrial Flutter: Rate and Rhythm Control

By Shreya Patel, Pharm.D., BCPS

Introduction	7
Current Guideline-Directed Care on Rate vs. Rhythm Control in AF	9
Rate Control in AF	10
Rhythm Control in AF	13
Antiarrhythmic Drugs to Restore Normal Sinus Rhythm in AF ..	13
Lifestyle Interventions	17
Conclusion	18
References	19
Self-Assessment Questions	21

Atrial Fibrillation/Atrial Flutter: Stroke Prevention

By Kazuhiko Kido, Pharm.D., MS, BCPS, BCCP

Introduction	25
Clinical Guideline Updates in Drug Therapy Management	26
Overview of OACS: VKAs vs DOACs	26
Selecting an Optimal Anticoagulation Regimen	34
Clinical Challenges with DOACs in Real-World Settings	37
Conclusion	37
References	38
Self-Assessment Questions	41

Arrhythmias and Thrombosis II	45
Arrhythmias and Thrombosis II Panel	47

DOAC Use in Special Populations

By Sarah Hanigan, Pharm.D., BCPS-AQ Cardiology, BCCP

Introduction	51
Special Populations – Patient Characteristics	51
Special Populations – Treatment Indications	60
Therapeutic Drug Monitoring	63
Conclusion	66
References	66
Self-Assessment Questions	70

Torsades de Pointes and Drug-Induced Arrhythmias

By Brian R. Overholser, Pharm.D., FCCP; and Kevin M. Sowinski, Pharm.D., FCCP

Introduction	75
Mechanisms of LQTS and TdP	78
Risk Factors for QT Interval Prolongation and TdP	79
Prevention	85
Management	86
Investigational Strategies and Potential Future Approaches ..	89
Conclusion	90

References	90
Self-Assessment Questions	93

Arrhythmias and Thrombosis III	97
Arrhythmias and Thrombosis III Panel	99

Venous Thromboembolism

By Nathan Clark, Pharm.D., FCCP, BCPS; and Naomi Y. Yates, Pharm.D., BCACP

Introduction	103
Epidemiology	103
Pathophysiology	104
Signs and Symptoms of VTE	105
Diagnosis of VTE	105
Treatment of Acute VTE	105
Determining the Duration of Therapy	112
Cancer-Associated VTE	113
Heparin and Heparinoids	115
Direct Oral Anticoagulants	117
Warfarin	119
Conclusion	119
References	119
Self-Assessment Questions	122

Bridging Anticoagulant Therapy

By James C. Coons, Pharm.D., FCCP, FACC, BCCP; and Taylor Miller, Pharm.D.

Introduction	125
Rationale and Evidence for Bridging	126
Evaluation of Patient Risk of TE and Bleeding	127
Evaluation of Procedural Risk of Bleeding in Patients Receiving AC ..	129
Periprocedural Warfarin Use	131
Periprocedural DOAC Use	133
Parenteral Bridging in the Periprocedural Setting	134
Post-Procedural Reinitiation of AC	135
Pathways, Protocols, and Quality Improvement	135
Conclusion	137
References	137
Self-Assessment Questions	141

Arrhythmias and Thrombosis IV	145
Arrhythmias and Thrombosis IV Panel	147

Recorded Webcast: Physical Examinations for Cardiovascular Medication Management

By Kristin Watson, Pharm.D., BCCP

Recorded Webcast: Physical Examinations for Cardiovascular Medication Management	153
Links to Associated Videos	154
Supplemental Information	154
Hyperlinks to activity	154
Self-Assessment Questions	156

Interactive Case: Shared Decision-making in the Management of CV Disorders

By Tracy E. Macaulay, Pharm.D., FCCP, FACC, BCCP

Interactive Case: Shared Decision-making in the Management of CV Disorders	159
Hyperlink to Activity	160
Self-Assessment Questions	162

Interactive Case: Management of Atrial Fibrillation in Patients Undergoing PCI

By Jessica Chasler, Pharm.D., MPH, BCCP

Interactive Case: Management of Atrial Fibrillation in Patients Undergoing PCI	168
Hyperlink to Activity	169
Self-Assessment Questions	171